Clemens Wendtner, MD from University of Cologne, Cologne, Germany, discusses the current and future diagnostics of chronic lymphocytic leukemia (CLL) at the British Society for Haematology (BSH) Annual Scientific Meeting in 2017. Prof. Wendtner states that there are currently several molecular and genetic markers to be considered before starting treatment. Apart from identifying 17p deletion and mutated TP53 genes by doing a fluorescent in situ hybridization (FISH) and TP53 mutation analysis, it is also worth checking the IGHV mutational status as not all drugs work for both unmutated and mutated IGHV cases; for example, FCR chemoimmunotherapy only works for mutated IGHV cases. Prof. Wendtner points out the application of modern techniques such as next-generation sequencing (NGS) in the future. He further discusses the possibility of screening for subclonal drivers to help indicate a more appropriate treatment when aggressive subclones are detected.